C2i Genomics, Karkinos Healthcare partner for cancer care (BioSpectrum India)
"C2i Genomics, a cancer intelligence company, announced a strategic partnership with Karkinos Healthcare, a technology-led managed care platform for cancer, to co-develop the minimal residual disease (MRD) market in India. The partnership enables C2i Genomics to bring innovative cancer detection technology to drive R&D, future pharma partnerships and clinical use in India and supports the company’s long-term goals to scale pharma R&D projects around the globe...The partnership will expand MRD monitoring within the Karkinos’ health system and its partners using the C2i Genomics’ ultrasensitive whole-genome analysis."